66 studies found for:    "Valganciclovir"
Show Display Options
Rank Status Study
1 Completed
Has Results
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Condition: Cytomegalovirus Infections
Intervention: Drug: Valganciclovir
2 Completed
Has Results
Valganciclovir to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Placebo
3 Recruiting ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Conditions: Kidney Transplantation;   Epstein-Barr Virus Infections/Complications;   Cytomegalovirus Infections/Complications
Interventions: Drug: Valacyclovir;   Drug: Valganciclovir
4 Terminated Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Condition: Allogeneic Stem Cell Transplantation
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
5 Completed Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Condition: Cytomegalovirus Infection
Intervention: Drug: Single arm (ganciclovir and valganciclovir)
6 Active, not recruiting Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Condition: Cytomegalovirus Disease
Interventions: Drug: Valganciclovir;   Biological: CMV hyperimmune globulin
7 Recruiting Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Condition: Infection in Solid Organ Transplant Recipients
Interventions: Drug: Ganciclovir/ Valganciclovir according to SPC;   Drug: Ganciclovir/ Valganciclovir according to PK model
8 Active, not recruiting
Has Results
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections
Condition: Cytomegalovirus Infection
Interventions: Drug: Placebo;   Drug: Valganciclovir
9 Terminated Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
10 Recruiting Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
Conditions: Congenital Cytomegalovirus Infection;   Sensorineural Hearing Loss
Intervention: Drug: Valganciclovir
11 Completed Valganciclovir in Congenital CMV Infants
Condition: Cytomegalovirus Infections
Interventions: Drug: Valganciclovir;   Drug: Ganciclovir
12 Completed Oral Valganciclovir Versus Valacyclovir
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Valganciclovir;   Drug: Valacyclovir
13 Active, not recruiting
Has Results
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Conditions: EBV Viremia;   CMV Viremia
Interventions: Drug: Valganciclovir;   Drug: Placebo
14 Withdrawn Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
Condition: Giant Lymph Node Hyperplasia
Intervention: Drug: Valganciclovir
15 Completed
Has Results
Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Condition: Cytomegalovirus Infections
Interventions: Drug: valganciclovir;   Other: Placebo
16 Completed Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
Condition: Sarcoma
Intervention: Drug: valganciclovir
17 Completed
Has Results
A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients
Condition: Kidney Transplantation, Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
18 Completed Suppression of Oral HHV8 Shedding With Valganciclovir
Condition: Human Herpesvirus 8
Interventions: Drug: valganciclovir;   Drug: placebo
19 Unknown  Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)
Conditions: Bone Marrow Transplantation;   Cytomegalovirus
Interventions: Drug: Valganciclovir;   Drug: Acyclovir
20 Unknown  Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Conditions: Heart Transplantation;   Cardiac Allograft Vasculopathy;   Cytomegalovirus Infection
Interventions: Drug: Pre-emptive strategy with valganciclovir plus everolimus;   Drug: Prophylaxis with valganciclovir plus mycophenolate;   Drug: Prophylaxis with valganciclovir plus everolimus;   Drug: Pre-emptive mycophenolate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years